Welcome to our dedicated page for Beam Therapeutics SEC filings (Ticker: BEAM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Beam Therapeutics Inc. filings document the regulatory record for a Nasdaq-listed biotechnology company developing base-editing genetic medicines. Its Form 8-K reports cover operating results, portfolio updates, senior secured credit facility terms, license and standby license arrangements for base-editing patent rights, board changes and Regulation FD presentations.
Proxy materials describe annual meeting matters, director elections, executive compensation, equity awards and stockholder voting procedures. The filings also identify Beam’s common stock, capital structure, material agreements and governance practices tied to its clinical-stage biotechnology business.
Beam Therapeutics Inc. Chief Legal Officer Christine Bellon reported sales of company common stock in open-market transactions on January 15, 2026, executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 16, 2025.
She sold blocks of Beam common stock at weighted-average prices of $33.6219, $34.7182 and $35.3988, with each price reflecting multiple trades within disclosed ranges. Following these sales, Bellon directly beneficially owned 97,038 shares of Beam common stock.
Christine Bellon filed a Rule 144 notice for the planned sale of 18,629 shares of BEAM common stock through Morgan Stanley Smith Barney LLC on NASDAQ. The shares to be sold have an aggregate market value of $644,830.69, while 101,474,944 shares of common stock are reported as outstanding. The filing lists these shares as common stock awards acquired as restricted stock from the issuer between March 31, 2022 and March 31, 2024. It also notes that in the previous three months, Bellon sold 1,254 common shares on January 2, 2026 for gross proceeds of $33,978.85. The approximate date for the new sale is January 15, 2026.
Beam Therapeutics Inc. reported in a current update that it estimates having approximately $1.25 billion in cash, cash equivalents and marketable securities as of December 31, 2025. This figure is preliminary, unaudited and may change as the company completes its year-end closing and prepares full financial statements, so the company cautions against placing undue reliance on the estimate.
Beam also highlighted progress across its base editing portfolio and described key anticipated milestones in a press release and updated corporate presentation furnished as exhibits. These materials will support upcoming conference appearances, including an investor presentation at the 44th Annual J.P. Morgan Healthcare Conference.
Beam Therapeutics Inc. (BEAM) filed its Q3 2025 10‑Q, reporting continued investment in R&D and a larger net loss. License and collaboration revenue was $9.7 million for the quarter. Research and development expense reached $109.8 million and general and administrative expense was $26.7 million. Net loss was $112.7 million, or $1.10 per share.
Liquidity remains strong. Cash and cash equivalents were $267.96 million and marketable securities were $807.01 million, totaling $1.07 billion as of September 30, 2025. The company closed an underwritten public offering in March 2025 for net proceeds of $470.5 million and reported operating cash outflows of $261.8 million for the nine months.
Strategic updates: Beam acquired an early‑stage life sciences company on July 1, 2025 for total consideration of $14.5 million, including 403,128 shares valued at $6.7 million and contingent consideration initially valued at $7.7 million; in‑process R&D of $14.5 million was expensed. Beam noted an announced agreement on October 10, 2025 for Bristol Myers Squibb to acquire Orbital Therapeutics; Beam holds 75 million Orbital shares.
Beam Therapeutics furnished a Form 8-K to announce its financial results for the quarter ended September 30, 2025.
The company issued a press release, furnished as Exhibit 99.1. The information in Item 2.02 and Exhibit 99.1 is furnished and is not deemed filed under Section 18 of the Exchange Act, nor incorporated by reference except as expressly stated.
Beam Therapeutics (BEAM): A reporting person disclosed an open‑market sale of 459 shares of common stock on 10/27/2025 at $26.68 per share (transaction code S). Following the transaction, indirect beneficial ownership positions were reported as 1,139,443 shares via F‑Prime Capital Partners Healthcare Fund V LP, 14 shares via FMR Capital, Inc., and 841,231 shares held by persons and entities whose shares are subject to reporting by the undersigned.
FMR LLC and related parties reported a disposition of Beam Therapeutics (BEAM) common stock. On 10/06/2025 the filing shows a disposal of 1,232,434 shares (transaction code G), leaving 841,231 shares beneficially owned following the transaction. The report lists additional indirect holdings: 1,139,443 shares held indirectly and 473 shares held by F-Prime Capital Partners Healthcare Fund V LP.
Remarks clarify that Abigail P. Johnson is a director, chair and CEO of FMR LLC and that members of the Johnson family collectively control 49% of FMR LLC voting power through Series B shares and a shareholders' voting agreement. The filing was signed on behalf of FMR LLC and affiliates by Stephanie J. Brown on 10/08/2025.
Beam Therapeutics insider Bethany J. Cavanagh, who serves as SVP, Finance and Treasurer, reported a non‑discretionary sale of 467 shares of common stock on 10/01/2025 at a price of $24.53 per share. The filing shows 44,045 shares remained beneficially owned by the reporting person after the transaction. The form states the shares were sold automatically to cover tax withholding obligations arising from the vesting of restricted stock units granted on 9/30/2021 and 9/30/2024, and the sales were effected under a Rule 10b5‑1 trading plan adopted on 8/9/2024. The Form 4 was signed by an attorney‑in‑fact on 10/03/2025.
Beam Therapeutics insider Christine Bellon, Chief Legal Officer, reported an automatic sale of 373 shares of common stock on 10/01/2025 at a price of $24.53 per share. The sale was made to satisfy tax withholding obligations triggered by the vesting of restricted stock units granted on 9/30/2021. The shares were sold under a Rule 10b5-1 trading plan adopted by the reporting person on 5/19/2023. After the transaction, the reporting person beneficially owned 116,921 shares.
John M. Evans, Beam Therapeutics Inc. CEO and director, reported option exercises and sales in early October 2025 under a Rule 10b5-1 plan. On 10/01/2025 and 10/02/2025 he exercised two stock option tranches at a $0.67 strike for 25,000 shares each and sold corresponding blocks of 25,000 shares on each date. The sales were executed as multiple transactions at weighted average prices of approximately $24.5062 (range $24.14–$24.92) and $24.6267 (range $24.22–$25.05). Following the reported acquisitions, Mr. Evans beneficially owned 1,011,667 shares directly and 103,000 shares indirectly via the John M. Evans, III 2018 Irrevocable Trust. The Form 4 notes the option grants dated 05/08/2018 with portions still exercisable and expiring on 05/08/2028, and that the trades were made pursuant to a trading plan adopted on 05/16/2025.